GB201300052D0 - Method for obtaining immuno-suppressive dendritic cells - Google Patents

Method for obtaining immuno-suppressive dendritic cells

Info

Publication number
GB201300052D0
GB201300052D0 GBGB1300052.6A GB201300052A GB201300052D0 GB 201300052 D0 GB201300052 D0 GB 201300052D0 GB 201300052 A GB201300052 A GB 201300052A GB 201300052 D0 GB201300052 D0 GB 201300052D0
Authority
GB
United Kingdom
Prior art keywords
dendritic cells
suppressive dendritic
obtaining immuno
immuno
obtaining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1300052.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TRANSIMMUNE AG
Yale University
Original Assignee
TRANSIMMUNE AG
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TRANSIMMUNE AG, Yale University filed Critical TRANSIMMUNE AG
Priority to GBGB1300052.6A priority Critical patent/GB201300052D0/en
Publication of GB201300052D0 publication Critical patent/GB201300052D0/en
Priority to PL14700050T priority patent/PL2941484T3/pl
Priority to KR1020157020667A priority patent/KR20150122639A/ko
Priority to CN201480003942.3A priority patent/CN104955940A/zh
Priority to KR1020207025108A priority patent/KR20200106217A/ko
Priority to HK15111385.3A priority patent/HK1210626B/en
Priority to EP20160436.0A priority patent/EP3719118A1/en
Priority to JP2015551179A priority patent/JP2016509474A/ja
Priority to ES14700050T priority patent/ES2795927T3/es
Priority to CN202111008277.5A priority patent/CN114410581A/zh
Priority to AU2014204346A priority patent/AU2014204346B2/en
Priority to CA2897113A priority patent/CA2897113C/en
Priority to EP14700050.9A priority patent/EP2941484B1/en
Priority to KR1020187002019A priority patent/KR20180010345A/ko
Priority to DK14700050.9T priority patent/DK2941484T3/da
Priority to PCT/EP2014/050012 priority patent/WO2014106631A1/en
Priority to US14/759,016 priority patent/US20160130552A1/en
Priority to JP2017205758A priority patent/JP6599958B2/ja
Priority to JP2019182703A priority patent/JP6804607B2/ja
Priority to US17/507,002 priority patent/US20220259556A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C12N5/064—Immunosuppressive dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/115—Platelets, megakaryocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2521/00—Culture process characterised by the use of hydrostatic pressure, flow or shear forces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2529/00—Culture process characterised by the use of electromagnetic stimulation
    • C12N2529/10—Stimulation by light

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB1300052.6A 2013-01-03 2013-01-03 Method for obtaining immuno-suppressive dendritic cells Ceased GB201300052D0 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
GBGB1300052.6A GB201300052D0 (en) 2013-01-03 2013-01-03 Method for obtaining immuno-suppressive dendritic cells
US14/759,016 US20160130552A1 (en) 2013-01-03 2014-01-02 Method for obtaining immuno-suppressive dendritic cells
ES14700050T ES2795927T3 (es) 2013-01-03 2014-01-02 Procedimiento para obtener células dendríticas inmunosupresoras
AU2014204346A AU2014204346B2 (en) 2013-01-03 2014-01-02 Method for obtaining immuno-suppressive dendritic cells
CN201480003942.3A CN104955940A (zh) 2013-01-03 2014-01-02 用于获得免疫抑制性树突细胞的方法
KR1020207025108A KR20200106217A (ko) 2013-01-03 2014-01-02 면역억제성 수지상 세포를 얻는 방법
HK15111385.3A HK1210626B (en) 2013-01-03 2014-01-02 Method for obtaining immuno-suppressive dendritic cells
EP20160436.0A EP3719118A1 (en) 2013-01-03 2014-01-02 Method for obtaining immuno-suppressive dendritic cells
JP2015551179A JP2016509474A (ja) 2013-01-03 2014-01-02 免疫抑制樹状細胞を得るための方法
PL14700050T PL2941484T3 (pl) 2013-01-03 2014-01-02 Sposób uzyskiwania komórek dendrytycznych tłumiących układ odpornościowy
CN202111008277.5A CN114410581A (zh) 2013-01-03 2014-01-02 用于获得免疫抑制性树突细胞的方法
KR1020157020667A KR20150122639A (ko) 2013-01-03 2014-01-02 면역억제성 수지상 세포를 얻는 방법
CA2897113A CA2897113C (en) 2013-01-03 2014-01-02 Method for obtaining immuno-suppressive dendritic cells
EP14700050.9A EP2941484B1 (en) 2013-01-03 2014-01-02 Method for obtaining immuno-suppressive dendritic cells
KR1020187002019A KR20180010345A (ko) 2013-01-03 2014-01-02 면역억제성 수지상 세포를 얻는 방법
DK14700050.9T DK2941484T3 (da) 2013-01-03 2014-01-02 Fremgangsmåde til at opnå immunsuppressive dendritriske celler
PCT/EP2014/050012 WO2014106631A1 (en) 2013-01-03 2014-01-02 Method for obtaining immuno-suppressive dendritic cells
JP2017205758A JP6599958B2 (ja) 2013-01-03 2017-10-25 免疫抑制樹状細胞を得るための方法
JP2019182703A JP6804607B2 (ja) 2013-01-03 2019-10-03 免疫抑制樹状細胞を得るための方法
US17/507,002 US20220259556A1 (en) 2013-01-03 2021-10-21 Method for obtaining immuno-suppressive dendritic cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1300052.6A GB201300052D0 (en) 2013-01-03 2013-01-03 Method for obtaining immuno-suppressive dendritic cells

Publications (1)

Publication Number Publication Date
GB201300052D0 true GB201300052D0 (en) 2013-02-20

Family

ID=47747914

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1300052.6A Ceased GB201300052D0 (en) 2013-01-03 2013-01-03 Method for obtaining immuno-suppressive dendritic cells

Country Status (12)

Country Link
US (2) US20160130552A1 (cg-RX-API-DMAC7.html)
EP (2) EP3719118A1 (cg-RX-API-DMAC7.html)
JP (3) JP2016509474A (cg-RX-API-DMAC7.html)
KR (3) KR20180010345A (cg-RX-API-DMAC7.html)
CN (2) CN104955940A (cg-RX-API-DMAC7.html)
AU (1) AU2014204346B2 (cg-RX-API-DMAC7.html)
CA (1) CA2897113C (cg-RX-API-DMAC7.html)
DK (1) DK2941484T3 (cg-RX-API-DMAC7.html)
ES (1) ES2795927T3 (cg-RX-API-DMAC7.html)
GB (1) GB201300052D0 (cg-RX-API-DMAC7.html)
PL (1) PL2941484T3 (cg-RX-API-DMAC7.html)
WO (1) WO2014106631A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013059343A1 (en) 2011-10-17 2013-04-25 Massachusetts Institute Of Technology Intracellular delivery
US10124336B2 (en) 2013-08-16 2018-11-13 Massachusetts Institute Of Technology Selective delivery of material to cells
GB201413665D0 (en) * 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
CN122564053A (zh) 2014-10-31 2026-08-14 麻省理工学院 递送生物分子至免疫细胞
WO2016077761A1 (en) 2014-11-14 2016-05-19 Massachusetts Institute Of Technology Disruption and field enabled delivery of compounds and compositions into cells
AU2016206870B2 (en) 2015-01-12 2022-02-17 Massachusetts Institute Of Technology Gene editing through microfluidic delivery
GB201513278D0 (en) * 2015-07-03 2015-09-09 Transimmune Ag And Yale University Device and method for obtaining immunostimulatory antigen-presenting cells
JP6925984B2 (ja) 2015-07-09 2021-08-25 マサチューセッツ インスティテュート オブ テクノロジー 無核細胞への物質の送達
US10946095B2 (en) 2015-09-02 2021-03-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human T-cell immunoglobulin and ITIM domain (TIGIT)
EP3518942A4 (en) * 2016-09-29 2020-05-27 Hadasit Medical Research Services&Development Ltd. DENDRITIC CELL PREPARATIONS, COMPOSITIONS AND METHODS OF USE
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN109701019B (zh) * 2019-01-04 2021-07-16 中国人民解放军第二军医大学 一种新的长链非编码RNA即lnc-Dpf3、其序列、免疫效应及用途
BR112021013193A2 (pt) 2019-01-07 2021-09-28 Shattuck Labs, Inc. Proteínas heterodiméricas para modulação de células t gama delta
KR102904431B1 (ko) * 2021-05-07 2025-12-26 (주)나노팬텍 수지상 세포의 배양 방법
WO2023283514A1 (en) * 2021-07-06 2023-01-12 Vanderbilt University Fluid shear stress for ex vivo activation of immune effector cells
EP4376860A1 (en) 2021-07-29 2024-06-05 Transimmune AG Methods for selectively reducing immunogenicity in a transplant
US20250375477A1 (en) * 2021-07-29 2025-12-11 Transimmune Ag Selective tolerization - methods of selectively generating tolerogenic dendritic cells
CN121335708A (zh) 2023-05-01 2026-01-13 耶鲁大学 用于疫苗接种的抗原特异性生理性树突状细胞
JP2026516460A (ja) 2023-05-01 2026-05-25 エール・ユニバーシティ 療法用の抗原特異的生理的樹状細胞
CN118256609B (zh) * 2024-02-06 2024-08-30 湖北文理学院 Tm9sf1标志物在监测自身免疫性疾病病程中的应用
WO2026074195A1 (en) 2024-10-05 2026-04-09 Yale University Cytokine loaded activated dendritic cells
WO2026074196A1 (en) 2024-10-05 2026-04-09 Yale University Checkpoint inhibitor loaded activated dendritic cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000062818A1 (en) 1999-04-20 2000-10-26 Richard Leslie Edelson Differentiation of monocytes into functional dendritic cells
US8524495B2 (en) * 2007-05-16 2013-09-03 Yale University Methods for inducing the differentiation of blood monocytes into functional dendritic cells
EP2358739A1 (en) * 2008-11-18 2011-08-24 The University Of Queensland Peptide conjugates for suppressing an immune response, methods of making and uses therefor

Also Published As

Publication number Publication date
AU2014204346B2 (en) 2017-08-31
EP2941484B1 (en) 2020-03-04
JP2018046837A (ja) 2018-03-29
US20160130552A1 (en) 2016-05-12
JP6599958B2 (ja) 2019-10-30
JP2016509474A (ja) 2016-03-31
KR20180010345A (ko) 2018-01-30
HK1210626A1 (en) 2016-04-29
CA2897113C (en) 2024-03-12
PL2941484T3 (pl) 2020-10-05
US20220259556A1 (en) 2022-08-18
CN104955940A (zh) 2015-09-30
JP6804607B2 (ja) 2020-12-23
ES2795927T3 (es) 2020-11-25
KR20150122639A (ko) 2015-11-02
DK2941484T3 (da) 2020-06-02
JP2020018315A (ja) 2020-02-06
EP2941484A1 (en) 2015-11-11
WO2014106631A1 (en) 2014-07-10
CA2897113A1 (en) 2014-07-10
CN114410581A (zh) 2022-04-29
AU2014204346A1 (en) 2015-07-02
KR20200106217A (ko) 2020-09-11
EP3719118A1 (en) 2020-10-07

Similar Documents

Publication Publication Date Title
PL2941484T3 (pl) Sposób uzyskiwania komórek dendrytycznych tłumiących układ odpornościowy
PL3741843T3 (pl) Sposób uzyskiwania komórek dendrytycznych stymulujących układ odpornościowy
GB2510821B (en) Charging Method
IL241627B (en) A method for t-cell activation
GB201309057D0 (en) Method
PL3052435T3 (pl) Sposób przechowania energii elektrycznej
ZA201400415B (en) Method for operating an electrolytic cell
EP3015544A4 (en) Cell release method
GB201309928D0 (en) Method
GB201313249D0 (en) Method
GB201301857D0 (en) Method
EP2817395A4 (en) PROCESS FOR THE PRODUCTION OF BIODIESEL
GB201300409D0 (en) Method
GB201309654D0 (en) Method
GB201305714D0 (en) Method
GB201301233D0 (en) Method
GB201311385D0 (en) Method
GB201301094D0 (en) Method
GB201511810D0 (en) Method for ion production
SG11201507338PA (en) Method for culturing cells
GB201312609D0 (en) Method
GB201314054D0 (en) Method
GB201311389D0 (en) Method
EP2947157A4 (en) METHOD FOR IDENTIFYING CELLS
GB201310354D0 (en) Method for cell differentiation

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)